Chi­nese vac­cine de­vel­op­ers have be­gun to shed some se­cre­cy around Covid-19 can­di­dates. What do we know?

Last No­vem­ber, Nisa Le­ung found her­self catch­ing up with Mar­garet Chan in a con­fer­ence at Bei­jing, won­der­ing when the next pan­dem­ic may be.

Le­ung, now a man­ag­ing part­ner at Qim­ing, had just grad­u­at­ed from busi­ness school at Stan­ford when she was asked to in­tro­duce in­fec­tious dis­ease ex­perts to Chan, then Hong Kong’s Sec­re­tary of Health. The year was 2003; the city was grap­pling with a lo­cal out­break of a dead­ly coro­n­avirus dis­ease — lat­er named the se­vere acute res­pi­ra­to­ry syn­drome, or SARS — that be­gan with a pa­tient ze­ro from main­land Chi­na.

“I still re­mem­ber very clear­ly that back then we tried to de­vel­op a di­ag­nos­tic test in Chi­na and we kind of just didn’t have the ca­pa­bil­i­ty,” Le­ung said. “And so we had to send the strains to the US for a com­pa­ny to de­vel­op it for us.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER